May 2023 in “Journal of Investigative Dermatology” Blocking DPP4 can potentially speed up hair growth and regeneration, especially after injury or in cases of hair loss.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
16 citations
,
January 2020 in “Diabetes” A new therapy sped up wound healing and reduced scarring in diabetic rats.
February 2026 in “Cureus” Combination therapy is better for long-term control and outcomes in type 2 diabetes.
7 citations
,
September 2019 in “European Journal of Case Reports in Internal Medicine” Linagliptin may cause hair loss and skin blisters.
3 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.
1 citations
,
November 2025 in “International Journal of Clinical Pharmacy” Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
19 citations
,
April 2019 in “Veterinary dermatology” Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
June 1992 in “The Journal of dermatologic surgery and oncology”
1 citations
,
July 2022 in “British Journal of Dermatology” Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
14 citations
,
April 2025 in “Nano Today” The hydrogel dressing speeds up and improves diabetic wound healing.
October 2024 in “Irish Journal of Medical Science (1971 -)” Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.
February 2024 in “Practical Diabetes” Spironolactone helps reduce hospital visits and death from heart issues, lowers blood pressure, but has unclear effects on heart failure with normal heart pump function and can cause high potassium and breast enlargement in men.
1 citations
,
November 2023 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib helps with early hair regrowth in people with alopecia areata.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
Using a combination of AMD3100 and FK506 can speed up and improve wound healing in diabetic rats.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
3 citations
,
April 2024 in “International Journal of Women’s Dermatology” Access to JAK inhibitor therapy for alopecia areata patients is difficult, especially for racial minorities.
April 2026 in “Science Progress” GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
4 citations
,
May 2025 in “Frontiers in Immunology” JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
January 2023 in “Discovery medicine” Cepharanthine helps reduce cell aging caused by the cancer drug Doxorubicin by boosting cell cleanup processes.
April 2026 in “Research Square” Dapagliflozin helps protect heart cells under stress by improving mitochondrial function and reducing cell damage.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
9 citations
,
July 2017 in “Case Reports in Dermatology” Combination therapy helped patient with advanced Hidradenitis Suppurativa achieve remission.